Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma
- 339 Downloads
- 1 Citations
Abstract
Diffuse intrinsic pontine glioma (DIPG) is an incurable disease with a median overall survival of 10 months. Immune modulating antibodies have recently emerged as a highly promising treatment modality in multiple cancer types. We present results from the first study to evaluate the immune modulating antibody MDV9300 (pidilizumab) in pediatric patients with DIPG. All patients aged 3 years and older, diagnosed with DIPG between February 2014 and June 2015 in Israel, were offered to participate in the study. Enrolled patients were started on biweekly 6 mg/kg MDV9300 after radiation completion. Treatment was continued until disease progression on imaging. Patients were followed biweekly for the occurrence of neurological deficit toxicities and side effects. Secondary endpoints were event free survival and overall survival. Of 13 children diagnosed with DIPG during the study period, nine were enrolled in the study. The patients underwent radiotherapy and none had chemotherapy. A total of 83 cycles of MDV9300 (range 2–16) were applied. The main side effects were neutropenia (CTCAE grade 1–3), mild to moderate fatigue, and acute elevation of blood pressure. Four patients died within 1 year of the diagnosis, another three died within 2 years and two children are still alive nearly 30 months from diagnosis, with stable disease. The median event free survival is 9.3 months (range 6.8–24) and the median overall survival is 15.6 months (range 6.9–28). Preliminary results demonstrate that MDV9300 treatment is safe and may be effective in the treatment of children with DIPG.
Keywords
Brain stem glioma Immunotherapy MDV9300 Pediatric oncologyNotes
Funding
Medication was provided by the company (CureTech Ltd. 42 Hayarkon St. Yavne 81227, Israel) no other funding was provided.
References
- 1.Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT (2011) Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg 115:505–511. doi: 10.3171/2011.4.JNS101172 CrossRefPubMedGoogle Scholar
- 2.Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248CrossRefPubMedGoogle Scholar
- 3.Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, Fisher D, Kearns P, Picton S, Saran F et al (2013) Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy: results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer 49:3856–3862. doi: 10.1016/j.ejca.2013.08.006 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol 13:410–416. doi: 10.1093/neuonc/noq205 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Kaye EC, Baker JN, Broniscer A (2014) Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis. CNS Oncol 3:421–431. doi: 10.2217/cns.14.47 CrossRefPubMedGoogle Scholar
- 6.Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PO, Zimmer J, Chekenya M (2013) Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 264:71–83. doi: 10.1016/j.jneuroim.2013.08.013 CrossRefPubMedGoogle Scholar
- 7.Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT (2013) Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 19:3165–3175. doi: 10.1158/1078-0432.CCR-12-3314 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343–349. doi: 10.1016/j.ijrobp.2012.12.025 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Castro MG, Baker GJ, Lowenstein PR (2014) Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier! Clin Cancer Res 20:5147–5149. doi: 10.1158/1078-0432.CCR-14-0820 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F et al (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:69–77. doi: 10.1016/S1470-204 CrossRefPubMedGoogle Scholar
- 11.Moreno B, Parisi G, Robert L, Ribas A (2015) Anti-PD-1 therapy in melanoma. Seminoncology 42:466. doi: 10.1053/j.seminoncol.2015.02.008 Google Scholar
- 12.Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, Heymans MW, Warmuth-Metz M, Hargrave D, van der Hoeven EJ, Gidding CE, de Bont ES, Eshghi OS et al (2015) Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol 17:160–166. doi: 10.1093/neuonc/nou104 CrossRefPubMedGoogle Scholar
- 13.Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14:3044–3051. doi: 10.1158/1078-0432.CCR-07-4079 CrossRefPubMedGoogle Scholar
- 14.Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR et al (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B cell lymphoma: results of an international phase II trial. J Clin Oncol 31:4199–4206. doi: 10.1200/JCO.2012.48.3685 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17:1064–1075. doi: 10.1093/neuonc/nou307 CrossRefPubMedGoogle Scholar
- 16.Dixit S (2014) Immunotherapy for high-grade glioma. Future Oncol 10:911–915. doi: 10.2217/fon.14.20 CrossRefPubMedGoogle Scholar
- 17.Efebera Y, Rosko A, Hofmeister C, Benner J, Bakan C, Stamper K, Lamb T, Hollie D, Sell M, Avigan D et al (2015) First interim results of a phase I/II study of lenalidomide in combination with anti-PD-1 monoclonal antibody MDV9300 (CT-011) in patients with relapsed/refractory multiple myeloma. Blood 126:1838Google Scholar
- 18.Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A et al (2014) Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2:831–838. doi: 10.1158/2326-6066.CIR-14-0069 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P et al (2015) Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7:967–980. doi: 10.2217/imt.15.65 CrossRefPubMedPubMedCentralGoogle Scholar